Cancer - Side effect drugs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cancer - Side effect drugs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who started this subject	5/18/2002 2:40:03 PM
From: John McCarthy	of 57

[2001]-[BNP7787]-[IPO Pulled] IPO Sector: Cancer drug developer BioNumerik Pharmaceuticals (San Antonio) said Friday it was pulling its $50-million initial public offering because of general market conditions. The company's lead product candidate, BNP7787, is being tested to prevent side effects, particularly nerve and kidney damage, from taxanes and platinum drugs, which are widely used to treat cancer. Elsewhere, medical camera company Digirad Corp. (San Diego) also on Friday withdrew a $69-million IPO, blaming current market conditions. The company, whose camera is used by doctors in medical procedures, had applied for a Nasdaq listing under the symbol "DRAD." UBS Warburg was going to handle the IPO. mondaymorning.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next